IP Library Granted Patent US 7,361,642
Granted Patent B2
US 7,361,642 · App. 10/894,644 · Granted Apr 22, 2008

Canine specific growth hormone releasing hormone

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,361,642
App. No.
10/894,644
Granted
Apr 22, 2008
Kind
B2
Abstract

A composition and a method of increasing growth hormone (“GH”) values in a canine or dog, and more specifically, a canine- or dog-specific growth hormone releasing hormone (“dGHRH”), or functional biological equivalent thereof. The dGHRH is an isolated composition or a nucleic acid molecule that encodes the dGHRH or functional biological equivalent. Also, a method for delivering the composition of this invention to a subject, wherein the dGHRH increases the level of growth hormone (“GH”) secretion in a recipient subject, such as a canine or dog.

Claims (15)

1. A composition comprising a nucleic acid expression construct that encodes the canine specific growth hormone releasing hormone (“dGHRH”) consisting of SEQ ID NO.: 04.

2. The composition of claim 1 , wherein the dGHRH increases growth hormone (“GH”) in a recipient subject.

3. The composition of claim 1 , wherein the dGHRH improves hematological parameters in a recipient subject.

4. The composition of claim 1 , wherein the dGHRH increases red blood cell values in a recipient subject.

5. The composition of claim 1 , wherein the dGHRH increases hemoglobin values in a recipient subject.

6. The composition of claim 1 , wherein the dGHRH increases mean corpuscular hemoglobin values in a recipient subject.

7. The composition of claim 1 , wherein the nucleic acid expression construct further comprises:

I. a synthetic or eukaryotic promoter;

II. a poly-adenylation signal;

III. a selectable marker gene promoter;

IV. a ribosomal binding site;

V. a selectable marker gene sequence; and

VI. an origin of replication.

8. The composition of claim 7 , wherein the polyadenylation signal comprises a portion of the human growth hormone 3′-untranslated region.

9. A composition comprising a nucleic acid expression construct that encodes the canine specific growth hormone releasing hormone consisting of SEQ ID NO.:03.

Assignments (4)
MERGER Recorded Feb 2, 2021
From: VGX PHARMACEUTICALS, LLC
To: INOVIO PHARMACEUTICALS, INC.
Reel/Frame 055114/0843 →
MERGER AND CHANGE OF NAME Recorded Dec 21, 2020
From: VGX PHARMACEUTICALS, INC.; INOVIO ACQUISITION, LLC
To: VGX PHARMACEUTICALS, LLC
Reel/Frame 054704/0830 →
MERGER Recorded Aug 1, 2007
From: ADVISYS INC.
To: VGX PHARMACEUTICALS, INC.
Reel/Frame 019628/0144 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2004
From: DRAGHIA-AKLI, RUXANDRA
To: ADVISYS, INC.
Reel/Frame 015892/0160 →